Despite the fact that ALM was retained in the ErbB2‘+’/ErbB3‘−’ MVM2 tumours at statistically greater levels than seen in blood (0.98±0.09 vs 0.28±0.04 %ID/g; P<0.001), the levels of targeting were significantly lower than those seen in either the BT-474 or SK-OV-3 xenograft models (P<0.001). The gene discussed is ERBB3; the disease is neoplasm.